Streetbeat News

Products Services

BRKR

Bruker Corporation (NASDAQ: BRKR) has launched two new high-performance systems at the 72nd ASMS meeting: the neofleX MALDI-TOF/TOF system for mass spectrometry-based tissue imaging and the timsTOF Ultra 2 system for deep profiling of small cells and subcellular organelles. These innovations are expected to set new standards in 4D-Proteomics.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:10 am

IPSC

Century Therapeutics presented interim results from its Phase 1 ELiPSE-1 study of CNTY-101 at the ASCO 2024 Annual Meeting. The study showed a manageable safety profile and encouraging preliminary efficacy in patients with relapsed or refractory CD19-positive B-cell malignancies. Enrollment continues in the dose escalation phase.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:08 am

TLSI

TriSalus Life Sciences (NASDAQ:TLSI) presented data from its Phase 1b PERIO-02 clinical trial at the ASCO 2024 Annual Meeting. The trial focuses on using the company's Pressure Enabled Drug Delivery™ (PEDD™) technology to enhance drug delivery in liver and pancreatic cancer treatments.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:08 am

COIN

DOGEUSD

PEPEUSD

BRETT, a meme coin launched in February 2024, has surpassed a $1 billion market cap, showing significant growth compared to other meme coins like Dogecoin and PEPE. The coin's recent listing on Seamless Protocol and positive indicators such as crypto ETF approvals and futures trading for Dogecoin on Coinbase Derivatives are fueling optimism for its future.

Portfolio Pulse from Murtuza Merchant

June 03, 2024 | 11:06 am

CLDI

Calidi Biotherapeutics Inc. (NYSE:CLDI) presented three abstracts at the 2024 ASCO Annual Meeting, including updates on their CLD-101 program and preclinical data on their RTNova (CLD-400) and CLD-201 platforms.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:06 am

RDHL

RedHill Biopharma announced a new Chinese patent notice of allowance for Opaganib in combination with immune checkpoint inhibitors as a method of inducing an anti-cancer immune response. This patent protects Opaganib's potential use through 2040.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:05 am

ALKS

Alkermes plc (NASDAQ:ALKS) announced new data from a phase 1b study of ALKS 2680, an investigational treatment for narcolepsy type 1, at the SLEEP 2024 conference. The study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug in ten patients.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:04 am

QNCX

The FDA has granted Fast Track designation to Quince Therapeutics' EryDex System for the treatment of Ataxia-Telangiectasia, a rare genetic disorder. This designation is expected to expedite the development and review process of the EryDex System.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:02 am

NVDA

ROK

Rockwell Automation has announced further collaborations with NVIDIA to enhance the development of safer and smarter industrial AI mobile robots. OTTO Motors, a division of Rockwell Automation, will create next-generation autonomous mobile robots using NVIDIA technologies.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:02 am

ACM

AECOM has secured a contract with FEMA to provide advisory and program management services to its four Consolidated Resource Centers. The contract includes a one-year base period with two one-year options.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 10:57 am